Affimed N.V. (AFMD) Reaches $2.08 After 9.00% Down Move; Laird PLC (LON:LRD) Covered By 8 Bullish Analysts Last Week

June 17, 2018 - By Adrian Mccoy

Laird PLC (LON:LRD) Logo

Among 11 analysts covering Laird PLC (LON:LRD), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Laird PLC had 75 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has “Overweight” rating by JP Morgan given on Tuesday, May 3. Numis Securities maintained the stock with “Buy” rating in Monday, December 21 report. Liberum Capital maintained Laird PLC (LON:LRD) rating on Monday, January 11. Liberum Capital has “Hold” rating and GBX 325 target. Numis Securities maintained the stock with “Add” rating in Friday, October 27 report. The rating was reinitiated by Numis Securities with “Hold” on Friday, April 21. The firm has “Buy” rating by Numis Securities given on Tuesday, December 1. On Monday, October 30 the stock rating was maintained by JP Morgan with “Overweight”. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, February 8. Numis Securities maintained the shares of LRD in report on Wednesday, March 9 with “Buy” rating. JP Morgan maintained Laird PLC (LON:LRD) on Monday, January 9 with “Neutral” rating. See Laird PLC (LON:LRD) latest ratings:

27/04/2018 Broker: Shore Capital Rating: Buy New Target: GBX 197.00 Maintain
01/03/2018 Broker: Shore Capital Rating: Buy Maintain
15/02/2018 Broker: Shore Capital Rating: Buy Maintain
08/02/2018 Broker: Stifel Nicolaus Rating: Buy Old Target: GBX 160.00 New Target: GBX 135.00 Upgrade
18/12/2017 Broker: Barclays Capital Rating: Equal-Weight Old Target: GBX 143.00 New Target: GBX 145.00 Reiteration

The stock of Affimed N.V. (NASDAQ:AFMD) is a huge mover today! The stock decreased 15.31% or $0.375 during the last trading session, reaching $2.075. About 2.81M shares traded or 533.01% up from the average. Affimed N.V. (NASDAQ:AFMD) has declined 6.38% since June 17, 2017 and is downtrending. It has underperformed by 18.95% the S&P500. Some Historical AFMD News: ; 23/04/2018 – EUROPEAN MEDICINES AGENCY VALIDATES TYPE Il VARIATION FOR MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH PEMETREXED (ALIMTA®) AND PLATINUM CHEMOTHERAPY AS FIRST-LINE THERAPY IN METASTATIC; 30/04/2018 – FDA Grants Priority Review to Merck’s sBLA for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and; 17/05/2018 – Oncolytics Biotech® Announces Collaboration with Merck and Northwestern University Combining Keytruda® and REOLYSIN® in a Ph; 17/05/2018 – Eisai Announces Data at ASCO 2018 Annual Meeting Showcasing LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy Under Strategic Oncology Collaboration with Merck; 09/04/2018 – KEYTRUDA® (PEMBROLIZUMAB) MONOTHERAPY MET PRIMARY ENDPOINT IN PHASE 3 KEYNOTE-042 STUDY, SIGNIFICANTLY IMPROVING OS AS FIRST-LINE THERAPY IN LOCALLY ADVANCED OR METASTATIC NSCLC PATIENTS EXPRESSING P…; 23/05/2018 – MERCK & CO INC – SAFETY PROFILE OF KEYTRUDA IN COMBINATION WAS CONSISTENT WITH THAT PREVIOUSLY OBSERVED IN LUNG CANCER; 23/04/2018 – Merck: EMA Validates Type II Variation for KEYTRUDA in Combination With Pemetrexed and Platinum Chemotherapy; 09/04/2018 – Merck: Keytruda Significantly Improves Overall Survival in Study; 06/04/2018 – INCYTE- SAFETY PROFILE OBSERVED IN ECHO-301/KEYNOTE-252 WAS CONSISTENT WITH THAT OBSERVED IN STUDIES OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA; 10/04/2018 – Oncolytics Biotech: Combination Therapy With REOLYSIN(R), Keytruda(R) and/or anti-CD73 Immunotherapy Led to Rejection of Pre-Established TumorsThe move comes after 6 months negative chart setup for the $129.46M company. It was reported on Jun, 17 by Barchart.com. We have $1.89 PT which if reached, will make NASDAQ:AFMD worth $11.65M less.

The stock increased 0.25% or GBX 0.5 during the last trading session, reaching GBX 200. About 9.77 million shares traded or 213.22% up from the average. Laird PLC (LON:LRD) has 0.00% since June 17, 2017 and is . It has underperformed by 12.57% the S&P500.

Laird PLC designs, manufactures, and supplies components and solutions in North America, Europe, Asia, and internationally. The company has market cap of 975.35 million GBP. The Company’s components and solutions protect electronic devices from electromagnetic interference and heat, and enable connectivity through wireless applications. It has a 12.66 P/E ratio. The firm operates in two divisions, Performance Materials and Wireless Systems.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. The company has market cap of $129.46 million. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. It currently has negative earnings. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.

Among 8 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Affimed Therapeutics had 17 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Affimed N.V. (NASDAQ:AFMD) has “Market Perform” rating given on Thursday, May 19 by Leerink Swann. Oppenheimer maintained Affimed N.V. (NASDAQ:AFMD) rating on Tuesday, August 1. Oppenheimer has “Buy” rating and $700 target. The stock of Affimed N.V. (NASDAQ:AFMD) has “Buy” rating given on Thursday, December 10 by Laidlaw. Jefferies initiated it with “Hold” rating and $11 target in Wednesday, September 9 report. The firm has “Hold” rating given on Thursday, May 19 by Jefferies. The stock has “Hold” rating by Jefferies on Thursday, August 31. The firm has “Market Perform” rating given on Friday, August 12 by Leerink Swann. The stock has “Hold” rating by Jefferies on Monday, June 12. The stock of Affimed N.V. (NASDAQ:AFMD) has “Outperform” rating given on Tuesday, April 12 by BMO Capital Markets. The firm earned “Outperform” rating on Friday, December 4 by Wells Fargo.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>